Printer Friendly

HOFFMANN-LA ROCHE EXECUTIVE TO BE KEYNOTE SPEAKER AT INTERPHEX USA

 NEW YORK, March 29 /PRNewswire/ -- Kenneth Berkowitz, vice president and director of public affairs for pharmaceutical giant Hoffmann-La Roche is the keynote speaker at this week's Interphex USA `93, the pharmaceutical industry's annual conference and exhibition (Javits Convention Center, New York City, March 30 - April 1, 1993).
 Berkowitz speaks at noon on Tuesday, March 30, to an audience eager to hear what is happening on the pharmaceutical industry's side of the fence regarding the Clinton administration's stance on regulations. What's ahead for the industry, and have the answers already been decided? Representation by the Pharmaceutical Manufacturers' Association will be visible during the keynote, and industry insiders expect some strong statements from Berkowitz.
 Berkowitz, a former attorney with the Federal Trade Commission, directs Roche's Public Policy, Public Relations, Community Affairs, Corporate Contributions, and Federal and State Government Affairs activities. Prior to his present position, he served as counsel to the company.
 Last year, he chaired the PMA task force on user fees. He serves on the board of directors of the New Jersey Association of Biomedical Research and also on the tough choices subcommittee of the National Committee for Quality Health Care; he is a recent appointee to the board of The National Health Council.
 Interphex USA `93, the Pharmaceutical Industry's exposition and conference, opens March 30 (the conference opens one day earlier on March 29) at the Jacob K. Javits Convention Center in New York City.
 For information, call the contact listed below.
 -0- 3/29/93
 /CONTACT: Interphex press office, 212-216-3320/


CO: Interphex USA '93 ST: New York IN: MTC SU:

LR-OS -- NY004 -- 0306 03/29/93 08:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 29, 1993
Words:271
Previous Article:DAMES & MOORE NAMES DR. PETER G. ROWLEY MANAGING DIRECTOR OF ITS INTERNATIONAL DIVISION
Next Article:NIH AWARDS SBIR GRANT TO PROGENICS PHARMACEUTICALS TO STUDY HIV LIFE CYCLE
Topics:


Related Articles
ALPHA 1 BIOMEDICALS COMPLETES ACQUISITION OF U.S. RIGHTS TO THYMOSIN ALPHA 1 FROM HOFFMANN-LA ROCHE
HOFFMANN-LA ROCHE TO PURSUE RESEARCH DESPITE DEMONSTRATION
INTERPHEX USA '93 OPENS MARCH 30 AT JAVITS CENTER
PROMEGA CORP. CHALLENGES KEY PATENT HELD BY HOFFMANN-LA ROCHE
GENSIA APPOINTS HERBERT CONRAD TO BOARD OF DIRECTORS
GENENTECH INTRODUCES PULMOZYME(R) IN THE UK
MILLENNIUM AND HOFFMANN-LA ROCHE SIGN COLLABORATIVE AGREEMENT TO APPLY GENOMICS TECHNOLOGIES TO TWO DISEASE AREAS
DURA PHARMACEUTICALS APPOINTS HERBERT CONRAD TO BOARD OF DIRECTORS
NEW APPROACH TO HIV DISEASE MANAGEMENT ADVOCATED AT HUMAN RETROVIRUSES CONFERENCE
BRISTOL-MYERS SQUIBB RESEARCH ALLIANCE WITH F.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters